Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma

International Journal of Urology

Volumn 13, Issue 11, 2006, Pages 1365-1370

  Ito, Keiichi ^a   Asano, Tomohiko ^a   Yoshii, Hidehiko ^a   Satoh, Akinori ^a   Sumitomo, Makoto ^a   Hayakawa, Masamichi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

C reactive protein; Prognostic factor; Renal cell carcinoma; Thrombocytosis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6;

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT; THROMBOCYTOSIS; TUMOR RECURRENCE; TUMOR VOLUME;

C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERLEUKIN-6; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PLATELET COUNT; PROGNOSIS; SURVIVAL RATE; THROMBOCYTOSIS;

EID: 33750430330     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01563.x     Document Type: Article

References (18)

1. Hannisdal E, Bostad L, Grottum KA et al. Erythrocyte sedimentation rate as a prognostic factor in renal cell carcinoma. Eur. J. Surg. Oncol. 1989; 15: 333-6.
2. Donmez T, Kale M, Ozyurek Y et al. Erythrocyte sedimentation rates in patients with renal cell carcinoma. Eur. Urol. 1992; 21: 51-2.
3. Miyata Y, Koga S, Nishikido M et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001; 58: 161-4.
4. Masuda H, Kurita Y, Fukuta K et al. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int. J. Urol. 1998; 5: 418-22.
5. Casamassima A, Picciariello M, Quaranta M et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J. Urol. 2005; 173: 52-5.
6. Fujikawa K, Matsui Y, Oka H et al. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J. Urol. 1999; 162: 1934-7.
7. O'Keefe SC, Marshall FF, Issa MM et al. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J. Urol. 2002; 168: 1378-80.
8. Inoue K, Kohashikawa K, Suzuki S et al. Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int. J. Urol. 2004; 11: 364-7.
9. Symbas NP, Townsend MF, El-Galley R et al. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000; 86: 203-7.
10. Gogus C, Baltaci S, Filiz E et al. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 2004; 63: 447-50.
11. Blay JY, Favrot M, Rossi JF et al. Role of interleukin-6 in paraneoplastic thrombocytosis. Blood 1993; 82: 2261-2.
12. Blay JY, Rossi JF, Wijdenes J et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer 1997; 72: 424-30.
13. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur. J. Cancer 1997; 33: 1794-8.
14. Blay JY, Negrier S, Combaret V et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52: 3317-22.
15. O'Byrne KJ, Dobbs N, Propper D et al. Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet 1999; 353: 1494-5.
16. Guinan P, Sobin LH, Algaba F et al. TNM staging of renal cell carcinoma: workgroup, 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 992-3.
17. Fujikawa K, Matsui Y, Miura K et al. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J. Urol. 2000; 164: 673-5.
18. Oya M, Takayanagi A, Horiguchi A et al. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003; 24: 377-84.